About Fibrocell Science
Fibrocell Science is a company based in Exton (United States) founded in 1995 was acquired by Castle Creek Pharma in September 2019.. Fibrocell Science has raised $34.66 million across 20 funding rounds from investors including Castle Creek Pharma, Precigen and EBMRF. Fibrocell Science operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Exton, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Fibrocell Science, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$34.66 M (USD)
in 20 rounds
-
Latest Funding Round
$900 K (USD), Post-IPO
Dec 20, 2018
-
Investors
Castle Creek Pharma
& 3 more
-
Employee Count
Employee Count
-
Acquired by
Castle Creek Pharma
(Sep 12, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Fibrocell Science
Fibrocell Science has successfully raised a total of $34.66M across 20 strategic funding rounds. The most recent funding activity was a Post-IPO round of $900 thousand completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 20
- Last Round Post-IPO — $900,000
-
First Round
First Round
(16 Jul 2002)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2018 | Amount | Post-IPO - Fibrocell Science | Valuation |
investors |
|
| Jul, 2018 | Amount | Post-IPO - Fibrocell Science | Valuation |
investors |
|
| May, 2018 | Amount | Post-IPO - Fibrocell Science | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Fibrocell Science
Fibrocell Science has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Castle Creek Pharma, Precigen and EBMRF. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research funding and awareness for Epidermolysis Bullosa are supported.
|
Founded Year | Domain | Location | |
|
Research funding is provided to cure Epidermolysis Bullosa.
|
Founded Year | Domain | Location | |
|
Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Fibrocell Science
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Fibrocell Science
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Fibrocell Science Comparisons
Competitors of Fibrocell Science
Fibrocell Science operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Fibrocell Science
Frequently Asked Questions about Fibrocell Science
When was Fibrocell Science founded?
Fibrocell Science was founded in 1995 and raised its 1st funding round 7 years after it was founded.
Where is Fibrocell Science located?
Fibrocell Science is headquartered in Exton, United States. It is registered at Exton, Pennsylvania, United States.
Is Fibrocell Science a funded company?
Fibrocell Science is a funded company, having raised a total of $34.66M across 20 funding rounds to date. The company's 1st funding round was a Post-IPO of $5.09M, raised on Jul 16, 2002.
What does Fibrocell Science do?
Fibrocell Science was founded in 1995 and is headquartered in Exton, United States. Autologous cell and gene therapies are developed by the company for conditions affecting the skin, connective tissue, and joints. The lead product candidate, FCX-007, targets linear scleroderma through gene therapy. Additional candidates for arthritis treatments are under development in the biotechnology sector.
Who are the top competitors of Fibrocell Science?
Fibrocell Science's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Who are Fibrocell Science's investors?
Fibrocell Science has 4 investors. Key investors include Castle Creek Pharma, Precigen, EBMRF, and EB Research Partnership.